# Tubulysin payloads

Source: https://onco.cc/terms/tubulysin-payloads/  
OnCo record `tubulysin-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tubulysins are another family of drugs that disrupt the cell's scaffolding. Antibody-linked versions are being studied to deliver their cell-killing action more selectively.

## Summary

Tubulysin derivatives are tubulin-directed payloads distinct from auristatins and maytansinoids. A primary comparison of tubulysin antibody conjugates found that conjugation mode and site changed payload stability, pharmacokinetics and efficacy in a gastric cancer xenograft model. Results from a peptide or small-molecule tubulysin conjugate should not be described as antibody-conjugate evidence.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: tubulysin antibody conjugates; tubulysin analog payloads

## Sources

- Tubulysin conjugation site, stability and efficacy study (2025): https://doi.org/10.1002/open.202400522

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/), [Tubulin inhibitor payloads](https://onco.cc/terms/tubulin-inhibitor-payloads/)

---
JSON: https://onco.cc/api/v1/entities/tubulysin-payloads.json